Sino Biopharmaceutical Limited (FRA:SMZ1)
Germany · Delayed Price · Currency is EUR | Market Cap | 8.49B -7.9% |
| Revenue (ttm) | 3.88B +10.3% |
| Net Income | 285.35M -33.0% |
| EPS | 0.02 -32.1% |
| Shares Out | n/a |
| PE Ratio | 29.76 |
| Forward PE | 14.96 |
| Dividend | 0.01 (2.28%) |
| Ex-Dividend Date | Jun 24, 2026 |
| Volume | n/a |
| Open | 0.4686 |
| Previous Close | 0.4840 |
| Day's Range | 0.4686 - 0.4870 |
| 52-Week Range | 0.4677 - 0.9926 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About Sino Biopharmaceutical
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules... [Read more]
Financial Performance
In 2025, Sino Biopharmaceutical's revenue was 31.83 billion, an increase of 10.28% compared to the previous year's 28.87 billion. Earnings were 2.34 billion, a decrease of -33.04%.
Financial numbers in CNY Financial StatementsNews
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment
GSK on Monday said it had entered into a strategic collaboration with Hong Kong-listed Sino Biopharmaceutical to accelerate the launch of its hepatitis B treatment bepirovirsen in mai...
Sino Biopharmaceutical Earnings release: H2 2025
Sino Biopharmaceutical released its H2 2025 earnings on March 26, 2026, summarizing the period's financial results.
Sino Biopharmaceutical Slides: H2 2025
Sino Biopharmaceutical has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 26, 2026.
Sino Biopharmaceutical Annual report: H2 2025
Sino Biopharmaceutical has published its H2 2025 annual report on March 26, 2026.
Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln
Hong Kong-listed Sino Biopharmaceutical said on Wednesday its unit has signed an exclusive global licensing deal with French drugmaker Sanofi worth up to $1.53 billion, giving the European pharma gi...
Sino Biopharmaceutical Quarterly report: H1 2025
Sino Biopharmaceutical has published its H1 2025 quarterly earnings report on August 17, 2025.
Sino Biopharmaceutical Earnings release: H1 2025
Sino Biopharmaceutical released its H1 2025 earnings on August 17, 2025, summarizing the period's financial results.
Sino Biopharmaceutical Slides: H1 2025
Sino Biopharmaceutical has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 17, 2025.
Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 mln
Hong Kong-listed Sino Biopharmaceutical will sell a 67% stake in unit CP Pharmaceutical (Qingdao) for 1.82 billion yuan ($253.28 million) to entities controlled by state-owned Guoxin Group, the compan...
China's health-care sector may be next to face regulatory crackdown, says economist
Dan Wang of Hang Seng Bank (China) says China's public health-care system is still expensive for ordinary people. The country's regulatory reform will be nationwide and have an international impact, s...
Chinese Company Gets FDA Approval For Drug To Fight Chemotherapy Nausea
Cancer killed far more people around the world than Covid-19 in 2020